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LETTER TO THE EDITOR
Chemotherapy Before
Liver Resection of
Colorectal Metastases:
Friend or Foe?
To the Editor:
W e read this systematic reviewwith greatinterest and congratulate the authors
on a comprehensive overview of the topic.1
There is a paucity of comparative studies of
neoadjuvant chemotherapy for resectable col-
orectal liver metastases (CRLM), making in-
terpretation of available case series data dif-
ficult. We disagree with their conclusion that
neoadjuvant therapy for resectable disease is
not recommended.
Since 1996, we pursued a policy
of neoadjuvant treatment followed by liver
resection for synchronous and early (<2
years) metachronous CRLM, and for late
metachronous CRLM with threatened resec-
tion margins. Our published 5-year survival
rate for 283 patients with completed resection
up to 2006was 46.1%.2 Over the 10 years, dif-
ferent chemotherapy regimens were used, re-
flecting the evolution of the standard of care.
We believe the good results support the asser-
tion that neoadjuvant therapy leads to control
of concurrent micrometastatic disease. This
is reflected in a significant partial or com-
plete tumor response rate, an increased rate
of clear resection margins and low repeat re-
section rate.3 We agree that neoadjuvant treat-
ment allows concentration of liver resection
in patients with better prognoses, as progres-
sion of disease while on chemotherapy is an
indicator of poor outcome. Although mortal-
ity is low, liver surgery is still associated with
significant morbidity and time lost to recov-
ery from surgery.Reserving surgical resection
for patients with favorable tumor biology is
sensible.
The authors quote a higher rate
of postchemotherapy-related complications.
However, this has not been our experience
as we limit neoadjuvant therapy to between
4 and 6 cycles, unless there are exceptional
circumstances.
We also question the authors’ asser-
tion that complete tumor response leading to
disappearing liver metastases (DLM) is un-
wanted and potentially detrimental. Complete
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pathological response signifies a chemosen-
sitive tumor and is associated with a high
rate of long-term survival.4 Although DLM
may present particular challenges intraopera-
tively and during posttreatment surveillance,
outcomes are still excellent with and without
a liver resection. Van Vledder et al5 found an
overall 5-year survival of 46.2% in patients
with resected DLM and 63.5% in patients
with DLM left in situ. Auer et al6 report an
actuarial 5-year survival of 65% in patients
with DLM.
With increasingly efficacious biolog-
ical and cytotoxic chemotherapeutic com-
pounds coming to market every year, the
paradigm of neoadjuvant therapy-resection-
adjuvant therapy is being applied success-
fully to gastrointestinal tract cancers, includ-
ing esophagogastric cancer and rectal cancer.
High rates of long-term survival and “cure”
can be achieved only with multimodal ther-
apy in patients with favorable tumor biol-
ogy. In the continuing absence of proven pre-
dictive disease-specific and pharmacogenetic
biomarkers, widespread utilization of upfront
chemotherapy for CRLM can be associated
with high rates of long-term survival, with
appropriate individualization of both surgi-
cal and chemotherapeutic oncological treat-
ments.
Ajay P. Belgaumkar, FRCS
Nadeen Low, FRACS
Angela T Riga, FRCS
Tim R. Worthington, MD, FRCS
Nariman D. Karanjia, MS, FRCS
Surrey and Sussex Regional HPB Unit
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Reply:
W e appreciate the comments by Bel-gaumkar, Worthington, and Karanjia
related to our article.1 In contrast to our rec-
ommendation, this group advocates the use
of neoadjuvant chemotherapy for resectable
colorectal liver metastases (CRLM) accord-
ing to their experience with 283 patients
treated between 1996 and 2006. Although
we would like to acknowledge the experi-
ence of this group, we must emphasize that
no comparative study is currently available
to demonstrate improved survival rates for
this population of patients using a neoadju-
vant chemotherapy approach. Their main ar-
gument for neoadjuvant chemotherapy is the
preoperative control of putative micrometas-
tases. We believe that the same argument can
be applied to the adjuvant approach with pos-
sibly additional advantages. For example, in-
traoperative tumor manipulation may lead to
tumor cell dissemination and therefore post-
operative chemotherapy may offer a better
control.2,3 Some data are available supporting
this concept, including the observation that a
regimen with 5-FU only disclosed a benefit
for CRLM in the adjuvant setting.4 Similarly,
a recent series in patients after cytoreductive
surgery for peritoneal carcinomatosis demon-
strated a benefit of adjuvant chemotherapy.5
Another argument to justify the use
of neoadjuvant chemotherapy is a better se-
lection of patients, who might benefit from
surgery.We believe that this strategy is worth-
while for borderline resectable lesions,6 but
not for the clearly resectable cases. Indeed,
patients with a large load of tumors or tumors
located in difficult areas in the liver may bene-
fit from chemotherapy before surgery and the
progressive case would likewise not benefit
from surgery.
Finally, Belgaumkar and colleagues
claim that the use of chemotherapy up to com-
plete disappearance of the lesion might be
beneficial and quote a paper by Adam et al6 to
support this. We would like to challenge such
an approach. Only a subset of disappearing
liver metastases on radiology examinations
are true pathologic responses.6,7 Evidence of
residual cancer cells has been documented in
up to 80% of disappeared liver metastases.8
Therefore, without radical resection, these ap-
parently cured lesions are associated with a
high rate of recurrence leading to unresectable
situations, when patients do not remain un-
der careful postoperative treatment.7 It must
be noted that favorable outcomes in patients
with missing metastases were only observed,
when hepatic intra-arterial chemotherapy was
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applied, or systemic chemotherapy was con-
tinued. Such strategy can be justified for ad-
vanced disease, but not in situations with re-
sectable liver metastases.
As stated in our analysis, current ev-
idence favors avoiding routine neoadjuvant
chemotherapy for patients with resectable
CRLM, which is in contrast to scenarios
with borderline metastatic load to the liver or
other hepatopancreaticobiliary tumors possi-
bly such as resectable pancreas tumors.9 Such
recommendations might change in the future
with the availability of new agents and con-
vincing studies.
Kuno Lehmann, MD
Pierre-Alain Clavien, MD, PhD, FACS
Swiss Hepato-Pancreatico-Biliary Center
Department of Surgery
University Hospital Zurich, Switzerland
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